SAB joins forces with Pennsylvania company to develop COVID-19 therapeutic
Sioux Falls-based SAB Biotherapeutics is joining with global biotherapeutics leader CSL Behring to rapidly develop SAB-185, a COVID-19 therapeutic candidate on track for clinical evaluation by early summer.